Triple-negative breast cancers doesn't always mean cancer spread

Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.

The study of 145 triple negative breast cancers (i.e, cancer which is estrogen receptor-negative, progesterone receptor-negative and HER2-negative) in 128 women found that about 23% were moderate or low-grade lesions, said Cecilia Mercado, MD, of New York University School of Medicine, and an author of the study.

Triple negative breast cancer is found in about 15% of breast cancer patients and the patients are usually younger.

The study found that 11 of the 145 cancers had a low histologic grade. Only one of these patients had evidence that their cancer had spread into their lymph nodes. Twenty-three cancers were moderate grade lesions; only five of these 23 had spread into the lymph nodes. That compares to 37 of 111 cancers with a high histologic grade which had lymph node metastases, Dr. Mercado said.

“Our preliminary results show that triple negative breast cancers are a heterogeneous group. Although many are high grade lesions, some are moderate or low grade demonstrating a lower rate of lymph node metastasis,” Dr. Mercado said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers uncover key genes linked to DCIS progression